Aeovian Pharmaceuticals raises $55 million in Series B financing to advance its selective mTORC1 inhibitor for TSC-related epilepsy, co-led by Luma Group and CTI Life Sciences Fund.
Amount Raised
$55 Million
Round Type
Series B
BerkeleyBiotechnologyHealthcareBiopharmaInvestors
Description
Aeovian Pharmaceuticals has closed an oversubscribed $55 million Series B financing to fund its Phase 2 clinical trial for AV078, a selective mTORC1 inhibitor. The round was co-led by Luma Group and CTI Life Sciences Fund, with support from multiple investors. Proceeds will advance AV078 into a Phase 2 proof-of-concept study targeting TSC-related refractory epilepsy. This study aims to address the complex challenges posed by current treatments that fail to target the underlying biology of seizures.
Quick answer
Aeovian Pharmaceuticals raised $55 Million in a Series B round, dated December 16, 2025. Investors: Symbiosis, venBio, Foresite Capital, Tsc Alliance Endowment Fund, Wilson Sonsini, Apollo Health Ventures, Hevolution and Sofinnova Investments. Aeovian Pharmaceuticals is based in Berkeley, California, United States.
- How much did Aeovian Pharmaceuticals raise?
- Aeovian Pharmaceuticals raised $55 Million in a Series B round on December 16, 2025.
- Who invested in Aeovian Pharmaceuticals?
- Symbiosis, venBio, Foresite Capital, Tsc Alliance Endowment Fund, Wilson Sonsini, Apollo Health Ventures, Hevolution and Sofinnova Investments are named as investors in this round.
- What does Aeovian Pharmaceuticals do?
- Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules to restore cellular metabolic quality control, thereby addressing the dysregulated growth..
- Where is Aeovian Pharmaceuticals based and how big is it?
- Aeovian Pharmaceuticals is based in Berkeley, California, United States.
- Who are the decision-makers at Aeovian Pharmaceuticals?
- Fundz holds 2 contacts at Aeovian Pharmaceuticals, including the Chief Medical Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Biopharma around the same time
Companies in the same sectors as Aeovian Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.
- Os Therapies raised $3.5M on January 14, 2026.
- Parabilis Medicines raised $305M (Series F) on January 8, 2026.
- Terns Pharmaceuticals raised $196M (Post-IPO Equity) on December 11, 2025.
- Artelo Biosciences raised $500K on January 30, 2026.
- Primmune Therapeutics raised $8.6M (Series B) on January 30, 2026.
- CytoDyn raised $19M on January 30, 2026.
Who to call at Aeovian Pharmaceuticals, and when
A new round usually means Aeovian Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Aeovian Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Aeovian Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Aeovian Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Aeovian Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAeovian Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.